Humanoid Output Tops 20,000 Units as Unitree Valuation Halves

Global humanoid robot output exceeded 20,000 units in 2025, ten times the 2024 level. Unitree's market capitalization fell below RMB 200 billion, more than 56% below its post-IPO high.

Deployment data offers the sharper test. Longcheer logged 64,828 executed tasks on its lines, while Maven Robotics runs eight wheeled warehouse units 16 hours a day at over 99% uptime. RoboSense is exiting full-robot assembly, selling that business to a related party for RMB 59.88 million, with the buyer 35% controlled by its chairman. Tesla's plan to convert its Fremont Model S/X line toward as much as 1 million Optimus units a year implies roughly a 25-fold capacity increase, placing the nearer-term scaling burden on component suppliers.

Capital is dividing along the same line. Kinetix AI raised over RMB 500 million and Westlake Robotics closed an A1 round in the hundreds of millions, both aimed at data-model-body loops; Maven's $100 million Series A went to wheeled hardware with measured uptime. Public markets, meanwhile, have repriced the listed leader.

Two technical markers are worth logging. AGIBOT describes GE-Act 2.0 as the first native World Action Model trained from scratch on embodied manipulation data, and Robbyant open-sourced LingBot-World 2.0, a real-time interactive world model that runs for hours. China's NHSA convened seven surgical robot makers and five hospitals on September 11, indicating that reimbursement rules will set the pace for that adjacent category.

Two observation points follow. Over the next two quarters, factory-side executed-task figures will show whether deployments move beyond case-by-case pilots into repeatable scale. Separately, reimbursement guidance for surgical robots will determine whether that category shifts from equipment sales toward reimbursable procedures.